Showing results (251-260 of 267) with videos related to
Sort By:
Pageof 27
Nature Medicine|January 16, 2019
Translation control of the immune checkpoint in cancer and its therapeutic targetingYichen Xu, Mauro Poggio, Hyun Yong Jin, et al.Journal of Medicinal Chemistry|May 30, 2020
Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA HelicaseJustin T Ernst, Peggy A Thompson, Christian Nilewski, et al.European Journal of Oral Sciences|February 4, 2010
IRF6 gene variants in Central European patients with non-syndromic cleft lip with or without cleft palateStefanie Birnbaum, Kerstin U Ludwig, Heiko Reutter, et al.Birth Defects Research. Part A, Clinical and Molecular Teratology|October 20, 2012
Resequencing of VAX1 in patients with nonsyndromic cleft lip with or without cleft palateEntessar Nasser, Elisabeth Mangold, Daniela C Tradowsky, et al.Journal of Medicinal Chemistry|May 3, 2002
Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C proteaseTheodore O Johnson, Ye Hua, Hiep T Luu, et al.Journal of Medicinal Chemistry|December 16, 1997
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 proteaseS W Kaldor, V J Kalish, J F Davies, et al.Molecular Cancer Therapeutics|October 10, 2020
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4APeggy A Thompson, Boreth Eam, Nathan P Young, et al.BMC Cancer|November 1, 2019
A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer CenterMarie K Budde, Walther Kuhn, Mignon-Denise Keyver-Paik, et al.Journal of Medicinal Chemistry|July 21, 1998
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studiesP S Dragovich, S E Webber, R E Babine, et al.Journal of Medicinal Chemistry|July 21, 1998
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studiesP S Dragovich, S E Webber, R E Babine, et al.Pageof 27